Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 5/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127857 | 0.89 | MEN1 (0.35) | ACHEACACBACACABCHEHTR2C | |
| SCHEMBL4130389 | 0.88 | ACHE (0.39) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4127747 | 0.86 | ACHE (0.38) | ACHEACACBACACABCHE | |
| Fumaric Acid SCHEMBL4127742 | 0.86 | ACHE (0.38) | ACHEACACBACACABCHE | |
| SCHEMBL4121348 | 0.83 | ACHE (0.41) | ACHEBCHE | |
| SCHEMBL4121344 | 0.82 | ACHE (0.39) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4113735 | 0.81 | ACHE (0.40) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4113738 | 0.81 | ACHE (0.40) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4113730 | 0.81 | ACHE (0.40) | ACHEBCHE | |
| SCHEMBL4126281 | 0.80 | CSF1R (0.42) | ACHEGPR119CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885GPR119 122/4885ACACB 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.